Identifying Plasma Proteins for Hypertrophic Cardiomyopathy Penetrance and Severity in Pathogenic Variant Carriers and Noncarriers
Year: 2026
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a clinically variable disease in onset and progression. Pathogenic MYBPC3 variants account for a substantial proportion of HCM diagnoses. OBJECTIVES: This study sought to identify protein biomarkers associated with HCM penetrance and severity. METHODS: Olink-assayed plasma proteins of 144 pathogenic MYBPC3 variant carriers were evaluated for associations with HCM severity based on diagnostic criteria (unaffected, mildly, or severely affected). Identified proteins were replicated in the UK Biobank considering time to onset of HCM (67 cases), cardiomyopathy (156 cases), and associations with left ventricular maximum wall thickness (6,492 participants). After prioritizing proteins on cardiac tissue expression and druggability, we examined disease penetrance through associations with heart failure (HF) and arrhythmic outcomes in 272 UK Biobank participants with known pathogenic HCM variants free of cardiomyopathy at proteomics assessment. RESULTS: Among pathogenic MYBPC3 variant carriers, we identified 27 proteins associated with HCM severity, of which 22 replicated in the UK Biobank. Six proteins were prioritized (N-terminal pro-B-type natriuretic peptide [NT-proBNP], growth/differentiation factor [GDF]-15, fibroblast growth factor [FGF]-23, adrenomedullin [ADM], renin [REN], and neural cell adhesion molecule 1 [NCAM1]), of which 5 associated with disease penetrance in pathogenic variant carriers: NT-proBNP and REN associated with increased HF and arrhythmic risk, GDF-15 and FGF-23 with HF risk, and NCAM1 with arrhythmic risk. CONCLUSIONS: Through the integration of proteomic analyses in both clinical and general population cohorts, we replicated and prioritized 6 proteins associated with HCM penetrance and severity. These findings highlight potential plasma-based markers for diagnosis and disease monitoring, as well as promising targets for future therapeutic development.
Source: JACC Advances
Authors: Fahima Hassanzada, Marion van Vugt, Mark Jansen, Annette F. Baas, Anneline S.J.M. te Riele, Dennis Dooijes, Saskia N. van der Crabben, Jan D.H. Jongbloed, Moniek G.P.J. Cox, Ahmad S. Amin, Ronald H. Lekanne Deprez, Bram Ruijsink, Diederik W.D. Kuster, Jolanda van der Velden, Connie R. Bezzina, Folkert W. Asselbergs, J. Peter van Tintelen, Karin Y. van Spaendonck-Zwarts, A. Floriaan Schmidt
Institutions: Utrecht University, University Medical Center Utrecht, ERN GUARD-Heart, Amsterdam UMC Location University of Amsterdam, Amsterdam University Medical Centers, Amsterdam Cardiovascular Sciences, University College London, University of Amsterdam, University Medical Center Groningen, King's College London, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam, National Institute for Health and Care Research, UCL Biomedical Research Centre
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,936
Funders: Bristol-Myers Squibb, Government of the United Kingdom, UK Research and Innovation, Dutch Cardiovascular Alliance, National Institute for Health and Care Research, British Heart Foundation, University College London, ZonMw, Nederlandse Organisatie voor Wetenschappelijk Onderzoek, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, UCLH Biomedical Research Centre, HORIZON EUROPE European Innovation Council
OpenAlex ID: W7143325819
